With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden ...

The study reported 10-year survival rates of 81.3% for ALL and 76.2% for AML post-HCT. Relapse and cGVHD were the primary causes of late mortality, with relapse contributing to 33.9% of ALL and 44.9% ...

Please provide your email address to receive an email when new articles are posted on . Patients with myeloid and monocytic leukemia are at increased risk for leukemia. Future prospective studies are ...

LEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 ...

Acute lymphocytic leukemia is one of the most commonly diagnosed cancers in children, although it is rare. It begins in the bone marrow and rapidly progresses. Long-term survival rates exceed 90%, but ...

Talk about a buzz kill. Cancer scientists at the University of Rochester are warning about a common ingredient in energy drinks that may drive the growth of myeloid leukemias, which affect the bone ...

Highlights in acute lymphoblastic leukemia (ALL), presented at the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition, include studies on pediatric and adult disease, as discussed ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in 97.8% of ...

As of May 11, 2026, 78 deaths had occurred in the study, called REGAL. ・On Tuesday, Sellas CEO said that the company expects the 80th event imminently. ・The CEO also expressed optimism for the ...